Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

@article{Costa2016PulseAF,
  title={Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.},
  author={Daniel Botelho Costa and Susan E Jorge and Jason P. Moran and Jason A Freed and Jessica A. Zerillo and Mark S. Huberman and Susumu S Kobayashi},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 6},
  pages={918-23}
}
INTRODUCTION Genomic aberrations involving the erb-b2 receptor tyrosine kinase 2 gene (ERBB2) are driver oncogenes in approximately 2% of lung adenocarcinomas. However, the use of daily dosing of ERBB2 tyrosine kinase inhibitors (TKIs)-including afatinib-has been fraught with plasma concentrations that barely achieve preclinical model inhibition… CONTINUE READING